Sleep Cycle B2B revenue rises 49.2% while total Q3 sales decline
Source publication date
Site published
Sleep Cycle reported Q3 2026 net sales of SEK50.863 million, down17.3% year-on-year, in its October 23 interim report. B2B revenue rose49.2% and reached19.7% of total sales. The report illustrates weakness in consumer subscriptions alongside growth in partner-facing sleep technology and SDK licensing.
The company reaffirmed an early-2027 plan to launch Apnea Alert as a Class I medical device in the EU and UK. A U.S. FDA submission and EU Class IIa remain potential next regulatory steps, not current approvals or availability. The proposed Audiowell acquisition also awaits a November 11 extraordinary general meeting decision. Source: https://investors.sleepcycle.com/pressreleases/sleep-cycle-interim-report-july-september-2026-ready-for-the-next-chapter
Summary
The October 23 report puts Q3 2026 net sales at SEK50.863 million, down17.3% year-on-year. B2B revenue grew49.2% and represented19.7% of total sales.
Editorial view
The results show a sleep-technology business expanding toward partner licensing while its consumer business remains under pressure.
Evidence and limitations
Figures refer to the company-reported July–September2026 period in SEK. Planned launches, regulatory pathways and a proposed transaction are not completed milestones. Diagnostic performance and FDA clearance were not independently verified.